HomeAI NewsIsomorphic Labs raises $5B Series C to push drug candidates toward trials

Isomorphic Labs raises $5B Series C to push drug candidates toward trials

Alphabet-backed lab spun out of DeepMind in 2021 plans to expand its AI drug-design engine into more medicine types.

Isomorphic Labs raised a $5 billion Series C round, the company announced, as the AI drug-discovery spinout from Google DeepMind works to move its drug candidates into clinical trials. Greenoaks and Sequoia Capital co-led the round, and Andreessen Horowitz joined as a new investor alongside all existing backers.

Isomorphic Labs spun out of DeepMind in 2021 and builds an AI drug-design engine that runs simulation models across chemistry to design drugs. Its work builds on AlphaFold, the protein-folding system that predicts 3D protein structure from genetic sequence. The lab reports positive preclinical results in oncology and immunology and holds deals with Eli Lilly, Novartis, and Johnson & Johnson.

For operators and research teams, the round signals that AI-native drug discovery now draws capital at scale, which puts pressure on biotech and pharma groups to evaluate external AI design partners rather than build every pipeline in house. The funding also lands after a $2.1 billion Series B in May, so the lab carries substantial runway to expand into more medicine types.

Isomorphic Labs did not disclose its new valuation. Bloomberg reported earlier this month that the company sought funding at a $50 billion valuation. The Series C is its first raise since founder and CEO Demis Hassabis stepped back from leading DeepMind to focus on drug discovery, and he now chairs DeepMind. The next signal is trial-stage data in oncology and immunology.

What matters

  • Greenoaks and Sequoia co-led the round, with Andreessen Horowitz joining as a new investor.
  • Drug discovery teams gain another well-funded AI engine competing for pharma partnerships.
  • Watch whether the $2.1 billion Series B plus this round moves candidates into human trials.

Why it matters

Watch whether the $2.1 billion Series B plus this round moves candidates into human trials.

This GenAI News article was prepared in original wording using reporting and materials published by TechCrunch AI. Source reference: https://techcrunch.com/2026/11/17/isomorphic-labs-raises-5b-as-it-looks-to-take-drug-candidates-to-clinical-trials/.

Drafted by the GenAI News review pipeline.

latest articles

explore more